In detail, tucatinib is an inhibitor of the human epidermal growth factor receptor tyrosine kinase ErbB-2 (also called HER2) used in combination with other medications (i.e., trastuzumab and capecitabine) to treat unresectable or metastatic HER-2-positive breast cancer. This evidence concerns the gene ERBB2 and breast carcinoma.